BioSpace News Archive

Resverlogix Corp. reminds stakeholders that the Company will hold a conference call and webcast on December 6th at 8:30 am ET to supplement the presentation of prespecified BETonMACE cognition results to be disclosed at the Clinical Trials on Alzheimer’s Disease Congress 2019.

The Canadian Medical Association is pleased to see Speech from the Throne reflect the need to increase our support for health care in Canada.

BridgeBio Pharma, Inc. announced that on November 22, 2019, the compensation committee of BridgeBio’s board of directors granted eight new employees options to purchase an aggregate of 62,745 shares of the Company’s common stock with a per share exercise price of $31.14 and restricted stock units for an aggregate of 23,980 shares of the Company’s common stock.

CIBI110A101 is a phase I clinical study conducted in China to evaluate IBI110 in the treatment of patients with advanced malignancies.

New Data Shows Clinical Evidence of Target Engagement and Target Validation

Health Canada is aware that some metformin products available outside Canada have been found to contain a nitrosamine impurity, N-nitrosodimethylamine, above the acceptable limit.

VISTASEAL™, a fibrin sealant developed by Grifols for biosurgical bleeding-control, is marketed and distributed by Ethicon and is the result of the two companies’ strategic collaboration

Thermo Fisher Scientific announced that the Ion Torrent Oncomine Myeloid Research Assay* will be available in 2020 to run on the newly introduced Ion Torrent Genexus System

Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application to proceed with a U.S. clinical trial of MV-012-968, an investigational vaccine for respiratory syncytial virus (RSV).

Akoya Biosciences, Inc., The Spatial Biology Company™, today announced the completion of a $50 million financing from both new and existing investors.